02 May 2003
PARP-1 involvement in growth inhibitory effects of temozolomide and topotecan in p53 wild-type (D54) and p53 mutated (U251) glioblastoma cells
S. Pepe, G. Cimmino, D. Melisi, G. Laus, S. Di Meglio, G. Tortora, A. Bianco, P. QuesadaMed Sci Monit 2003; 9(1): 56-0 :: ID: 15121
Abstract
Malignant gliomas occur more frequently than other types of primary central nervous system tumors. Among the chemotherapic agents, temozolomide (TZM) and topotecan (TPT) represent important new drugs active in such neoplastic diseaseas. Moreover, preclinical studies have evaluated the combination of these agents and inhibitors of the DNA repair enzymes [1].In the present study we investigated cell growth inhibition and cell cycle perturbation induced by TPT or TZM treatment in the presence of the specific PARP-1 inhibitor NU 1025 in two gliobastoma cell lines, the D54 (p53 wt) and the U251 (p53 mut). Agar-colony-forming assay showed a different sensitivity of both cell lines to TPT or TZM. Moreover, combined treatment with TZM and non cytotoxic concentration of NU1025 induced a 25% increase of growth inhibition in D54 and U251; the same additive effect was observed mainly in U251 for TPT plus NU1025 treatment. DNA-flow cytometry showed that TZM and TPT induce an accumulation of cells in G2M phase of cell cycle and that PARP-1 inhibitor addition doubled G2M block in TZM treated cells.The characterization of the poly(ADP-ribosyl)ation system in both glioblastoma cell lines is in progress and particular attention will be made to define PARP-1 involvement in p53 dependent and independent signal transduction system.References: 1.Friedman SH, Kerby T, Calvert H: Clin Cancer Res, 2000; 6: 2585-2597
Keywords: PARP-1, temozolomide, Topotecan, p53, Cells
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952